ESR1 and breast carcinoma: The primary endpoint, of improving invasive disease-free survival (iDFS) in ERα+, HER2− breast cancer patients who had residual invasive disease after completing neoadjuvant chemotherapy (the phase 3 PENELOPE-B) was not met.